GE HealthCare Technologies Inc (Nasdaq: GEHC) shares closed higher on Wednesday following the release of fourth-quarter and full-year 2025 results, with the stock finishing at about $82.55, up from prior session levels and reflecting a notable intraday gain in volatile trading.
GE HealthCare Technologies Inc is listed on the Nasdaq exchange. At Wednesday’s close, the stock price was $82.55, up intraday versus the prior close, reflecting market focus on earnings and guidance.
Market Capitalization
As of the latest market close, GE HealthCare’s market capitalization stood near $36 billion.
Latest Quarterly Results
For the fourth quarter ended December 31, 2025, GE HealthCare reported total revenue of $5.7 billion, up 7.1% year-over-year with organic revenue growth of 4.8%. Net income attributable to the company was $589 million, with an overall net income margin of 10.3%. On a diluted basis, earnings per share (EPS) were $1.29, while adjusted EPS, which excludes certain items, was $1.44. Cash flow from operating activities for the quarter was $1.0 billion, and free cash flow was $916 million.
Segment revenues for the quarter were:
• Imaging: $2,552 million, up about 6.6% year-over-year (organic +5.3%).
• Advanced Visualization Solutions: $1,525 million, up roughly 5.9% (organic +4.2%).
• Patient Care Solutions: $825 million, a slight decline (organic -0.3%, -1.1% organically).
• Pharmaceutical Diagnostics: $790 million, up about 22.3% (organic +12.7%).
Segment EBIT and margin trends showed mixed performance across units.
Full-Year Results
GE HealthCare reported for the full year 2025 a consolidated revenue of $20.6 billion, up 4.8% compared to 2024 with organic revenue growth of 3.5%. Net income attributable to the company was $2.1 billion, and adjusted EPS was $4.59 versus $4.49 in 2024. Full year cash flow from operating activities was $2.0 billion, and free cash flow reached $1.5 billion.
Business & Operations Update
GE HealthCare continued segment expansion and operational partnerships across its imaging and diagnostics portfolios. The company has received regulatory clearances and first installations for new imaging platforms, advancing product availability in interventional suites. It also entered collaborations such as a multi-year care alliance with a major medical center to broaden diagnostic and monitoring capabilities.
In 2025, GE HealthCare expanded its portfolio with acquisitions completed for certain diagnostic and analytics businesses, and announced planned strategic acquisitions to extend cloud-based imaging solutions.
Executing on Strategy
Through 2025, GE HealthCare reported progress on its stated strategic pillars, including precision care, growth acceleration, and business optimization. The company focused on innovation investment, recurring revenue growth, and mitigation of tariff impacts on supply chain costs. In 2025, the company focused on its “Heartbeat” business system, which management stated contributed to a 25% reduction in past-due backlog.
Equity Analyst Commentary
Market commentary noted the earnings beat and positive outlook, with analysts citing revenue growth in core diagnostic and imaging businesses and profit guidance exceeding consensus estimates. Such commentary reflected institutional research observations on recent reported results.
Guidance & Outlook
GE HealthCare issued guidance for 2026 that includes expected organic revenue growth of 3%–4%, an adjusted EBIT margin range of 15.8%–16.1%, and adjusted EPS between $4.95 and $5.15. The company highlighted tariff impact reduction and continued capital investment as areas to monitor.
Performance Summary
GE HealthCare shares moved higher on the day’s trading following earnings and guidance. The fourth quarter saw revenue and adjusted EPS above year-ago levels with solid segment performance. Full-year revenue and profit grew on a comparative basis. Company guidance for 2026 frames key metrics to watch.